427 479

Cited 38 times in

Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김준원-
dc.contributor.author성진실-
dc.contributor.author우중열-
dc.contributor.author이익재-
dc.contributor.author한광협-
dc.date.accessioned2017-10-26T07:18:05Z-
dc.date.available2017-10-26T07:18:05Z-
dc.date.issued2016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/151855-
dc.description.abstractBACKGROUND: Phase I trial was conducted to determine feasibility and toxicity of helical intensity-modulated radiotherapy (IMRT)-based stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). RESULTS: Eighteen patients (22 lesions) were enrolled. With no DLT at 52 Gy (13 Gy/fraction), protocol was amended for further escalation to 60 Gy (15 Gy/fraction). Radiologic complete response rate was 88.9%. Two outfield intrahepatic, 2 distant, 4 concurrent local and outfield, and 1 concurrent local, outfield and distant failures (no local failure at dose levels 3-4) occurred. The worst toxicity was grade 3 hematologic in five patients, with no gastrointestinal toxicity > grade 1. At median follow-up of 28 months for living patients, 2-year local control, progression-free (PFS), and overall survival rates were 71.3%, 49.4% and 69.3%, respectively. Multi-segmental recurrences prior to SBRT was independent prognostic factor for PFS (p = 0.033). MATERIALS AND METHODS: Eligible patients had Child-Pugh's class A or B, unresectable HCC, ≤ 3 lesions, and cumulative tumor diameter ≤ 6 cm. Starting at 36 Gy in four fractions, dose was escalated with 2 Gy/fraction per dose-level. CTCAE v 3.0 ≥ grade 3 gastrointestinal toxicity and radiation induced liver disease defined dose-limiting toxicity (DLT). CONCLUSIONS: Helical IMRT-based SBRT was tolerable and showed encouraging results. Confirmatory phase II trial is underway.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherImpact Journals-
dc.relation.isPartOfONCOTARGET-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHCarcinoma, Hepatocellular/radiotherapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/radiotherapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local/pathology-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiometry-
dc.subject.MESHRadiosurgery/methods*-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRadiotherapy, Intensity-Modulated/methods*-
dc.subject.MESHTreatment Outcome-
dc.titlePhase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiation Oncology-
dc.contributor.googleauthorJun Won Kim-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorIk Jae Lee-
dc.contributor.googleauthorJoong Yeol Woo-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.18632/oncotarget.9450-
dc.contributor.localIdA01956-
dc.contributor.localIdA04981-
dc.contributor.localIdA03055-
dc.contributor.localIdA04268-
dc.contributor.localIdA00958-
dc.relation.journalcodeJ02421-
dc.identifier.eissn1949-2553-
dc.identifier.pmid27213593-
dc.subject.keyworddose escalation-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordintensity-modulated radiotherapy-
dc.subject.keywordstereotactic body radiotherapy-
dc.contributor.alternativeNameKim, Jun Won-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameWoo, Joong Yeol-
dc.contributor.alternativeNameLee, Ik Jae-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorWoo, Joong Yeol-
dc.contributor.affiliatedAuthorLee, Ik Jae-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Jun Won-
dc.citation.volume7-
dc.citation.number26-
dc.citation.startPage40756-
dc.citation.endPage40766-
dc.identifier.bibliographicCitationONCOTARGET , Vol.7(26) : 40756-40766, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid46180-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.